Clinical activity of arsenic trioxide for the treatment of multiple myeloma
- 30 August 2002
- journal article
- clinical trial
- Published by Springer Nature in Leukemia
- Vol. 16 (9), 1835-1837
- https://doi.org/10.1038/sj.leu.2402599
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Arsenic Trioxide: An Emerging Therapy for Multiple MyelomaThe Oncologist, 2001
- The biology of multiple myelomaZeitschrift für Krebsforschung und Klinische Onkologie, 2000
- Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalitiesBlood, 2000
- PROGNOSTIC FACTORS IN MULTIPLE MYELOMAHematology/Oncology Clinics of North America, 1999
- Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia PatientsBlood, 1999
- Arsenic Trioxide Selectively Induces Acute Promyelocytic Leukemia Cell Apoptosis Via a Hydrogen Peroxide-Dependent PathwayBlood, 1999
- Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable ConcentrationsJNCI Journal of the National Cancer Institute, 1999
- Long-term follow-up after high-dose therapy for high-risk multiple myelomaBone Marrow Transplantation, 1998
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell supportBlood, 1992